Tokyo, Sept. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058902) titled 'A retrospective observational study to investigate the impact of the severity of ptosis on visual functions' on Sept. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Santen Pharmaceutical Co., Ltd.
Condition:
Condition - Ptosis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To exploratorily investigate the impact of the severity of ptosis on visual functions in patients with ptosis through a retrospective observational study.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with ptosis who visited the study site during the study period (June 2025 - August 2025) who met all of the following criteria will be eligible.
1) 18 years of age or older (at the time of visit)
2) MRD-1, visual acuity, refraction, visual field, contrast sensitivity, and higher-order aberration measured on the same day for the right eye
Key exclusion criteria - None
Target Size - 200
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 08 Month 04 Day
Date of IRB - 2025 Year 08 Month 18 Day
Anticipated trial start date - 2025 Year 09 Month 01 Day
Last follow-up date - 2026 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067362
Disclaimer: Curated by HT Syndication.
